Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 21, 2010, Pages 9801-9806

  Simon, Anna ^a,b   Park, Heiyoung ^a   Maddipati, Ravikanth ^a   Lobito, Adrian A ^a,c   Bulua, Ariel C ^a   Jackson, Adrianna J ^a   Chae, Jae Jin ^a   Ettinger, Rachel ^a,d   De Koning, Heleen D ^a,b   Cruz, Anthony C ^a   Kastner, Daniel L ^a   Komarow, Hirsh ^a   Siegel, Richard M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GENENTECH INC   (United States)

^d MEDIMMUNE   (United States)

Author keywords

Autoinflammatory disease; Genetic disease

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ANIMALS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; LIPOPOLYSACCHARIDES; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

MUS;

EID: 77953089570     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914118107     Document Type: Article

References (38)

1. Micheau O, Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190.
2. Chen G, Goeddel DV (2002) TNF-R1 signaling: A beautiful pathway. Science 296: 1634-1635.
3. McDermott MF, et al. (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133-144.
4. Kimberley FC, Lobito AA, Siegel RM, Screaton GR (2007) Falling into TRAPS - receptor misfoldingin the TNF receptor 1-associatedperiodic fever syndrome. ArthritisRes Ther 9:217.
5. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-241.
6. McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3:e297.
7. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621-668.
8. Touitou I, et al. (2004) Infevers: An evolving mutation database for auto-inflammatory syndromes. Hum Mutat 24:194-198.
9. Tchernitchko D, et al. (2005) Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet 13:513-515.
10. Ravet N, et al. (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65:1158-1162.
11. Gattorno M, et al. (2008) A diagnostic score for molecular analysis of hereditary auto-inflammatory syndromes with periodic fever in children. Arthritis Rheum 58:1823-1832.
12. Huggins ML, et al. (2004) Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: Differences between cell types. Arthritis Rheum 50:2651-2659.
13. Hull KM, et al. (2002) The TNF receptor-associated periodic syndrome (TRAPS): Emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81:349-368.
14. Arostegui JI, et al. (2005) Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodeswithout normalising the subclinical acute phase response.Eur J Pediatr 164:13-16.
15. Jacobelli S, Andre M, Alexandra JF, Dode C, Papo T (2007) Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1211-1212.
16. Lobito AA, et al. (2006) Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108:1320-1327.
17. Todd I, et al. (2007) Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum 56:2765-2773.
18. Rebelo SL, et al. (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 54:2674-2687.
19. Todd I, et al. (2004) Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor- associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 113:65-79.
20. Zhang K, et al. (2006) Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell 124:587-599.
21. Kamata H, et al. (2005) Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649-661.
22. Tang F, et al. (2002) The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes totumornecrosis factor alpha-inducedapoptosis. Mol Cell Biol 22:8571-8579.
23. Sheehan KC, et al. (1995) Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: Identification of a novel in vivo role for p75. J Exp Med 181:607-617.
24. Peschon JJ, et al. (1998) TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160:943-952. (Pubitemid 28049339)
25. Bultinck J, Brouckaert P, Cauwels A (2006) The in vivo contribution of hematopoietic cells to systemic TNF and IL-6 production during endotoxemia. Cytokine 36:160-166.
26. Rothe J, et al. (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802.
27. Blanque R, Meakin C, Millet S, Gardner CR (1996) Hypothermia as an indicator of the acute effects of lipopolysaccharides: Comparison with serum levels of IL1 beta, IL6 and TNF alpha. Gen Pharmacol 27:973-977. (Pubitemid 26345049)
28. Silverstein R (2004) D-galactosamine lethality model: Scope and limitations. J Endotoxin Res 10:147-162.
29. Leon LR, White AA, Kluger MJ (1998) Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol 275:R269-R277. (Pubitemid 28376317)
30. Remick D, et al. (1995) Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4:89-95.
31. Nowlan ML, et al. (2006) Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 45:31-37.
32. Bruijn LI, et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive diseasewith SOD1-containing inclusions. Neuron 18:327-338.
33. Xanthoulea S, et al. (2004) Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 200:367-376.
34. Goldbach-Mansky R, et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581-592.
35. van Deuren M, et al. (1998) Elective orthopedic surgery, a model for the study of cytokine activation and regulation. Cytokine 10:897-903.
36. van Deuren M, et al. (1994) Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 169:157-161. (Pubitemid 24976907)
37. Bodar EJ, Drenth JP, Simon A, van der Meer JW (2007) Ned Tijdschr Geneeskd 151: 836-837, author reply 837.
38. Ettinger R, et al. (2001) A critical role for lymphotoxin-beta receptor in the development of diabetes in nonobese diabetic mice. J Exp Med 193:1333-1340.